United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
526.60
+5.38 (1.03%)
Mar 24, 2026, 11:06 AM EDT - Market open
United Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts that cover United Therapeutics stock have a consensus rating of "Buy" and an average price target of $533.21, which forecasts a 1.26% increase in the stock price over the next year. The lowest target is $330 and the highest is $705.
Price Target: $533.21 (+1.26%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 4 | 4 | 5 | 5 |
| Buy | 5 | 4 | 4 | 4 | 4 | 5 |
| Hold | 5 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 12 | 12 | 12 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $466 → $486 | Hold | Maintains | $466 → $486 | -7.71% | Mar 23, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $525 → $625 | Buy | Maintains | $525 → $625 | +18.69% | Mar 12, 2026 |
| UBS | UBS | Strong Buy Maintains $655 → $705 | Strong Buy | Maintains | $655 → $705 | +33.88% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $525 → $600 | Strong Buy | Maintains | $525 → $600 | +13.94% | Feb 26, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $525 → $575 | Strong Buy | Maintains | $525 → $575 | +9.19% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
3.41B
from 3.18B
Increased by 7.05%
Revenue Next Year
3.86B
from 3.41B
Increased by 13.30%
EPS This Year
29.87
from 27.86
Increased by 7.21%
EPS Next Year
33.42
from 29.87
Increased by 11.88%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.7B | 4.5B | |||
| Avg | 3.4B | 3.9B | |||
| Low | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.2% | 32.3% | |||
| Avg | 7.0% | 13.3% | |||
| Low | -2.7% | -7.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 36.33 | 40.38 | |||
| Avg | 29.87 | 33.42 | |||
| Low | 25.20 | 22.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 30.4% | 35.2% | |||
| Avg | 7.2% | 11.9% | |||
| Low | -9.6% | -23.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.